SEARLE's CYTOTEC (MISOPROSTOL) CLEARS FDA FOR NSAID-RELATED ULCERS; COMPANY SAYS CURRENT MARKET FOR CONCOMITANT USE IS $500 MIL. ANNUALLY

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".